Based on the median expression value of DR6 in CRC tumor tissues, we divided 100 CRC patients into two groups: DR6 high-expression group (n = 50) and DR6 low-expression group (n = 50). This evidence concerns the gene TNFRSF21 and colorectal carcinoma.